2. Search Result
Search Result
Results for "

redox mediator

" in MedChemExpress (MCE) Product Catalog:

43

Inhibitors & Agonists

2

Fluorescent Dyes

3

Biochemical Assay Reagents

3

Peptides

9

Natural
Products

13

Isotope-Labeled Compounds

2

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13948
    Angiotensin II human
    Maximum Cited Publications
    222 Publications Verification

    Angiotensin II; Ang II; DRVYIHPF

    		 Angiotensin Receptor Apoptosis Cardiovascular Disease Infection Metabolic Disease Inflammation/Immunology Cancer
    Angiotensin II (Angiotensin II) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human also induces apoptosis. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
    Angiotensin II human
  • HY-113324
    NADPH
    15+ Cited Publications

    		 Endogenous Metabolite Cancer
    NADPH is a coenzyme of glutathione reductase (GR), thioredoxin reductase (TrxR) and NADPH oxidase (NOX), and participates in redox reactions as a hydrogen donor. NADPH has the characteristic of selectively participating in the regulation of cellular redox homeostasis. NADPH exerts antioxidant activity and resists reactive oxygen species (ROS) damage by providing reducing equivalents for the regeneration of glutathione (GSH) and thioredoxin (Trx); at the same time, it acts as a substrate of NOX to generate superoxide anions, mediating oxidative stress and immune response. NADPH participates in maintaining the intracellular reducing environment, biosynthesis and regulating gene expression (such as the Nrf2 pathway), and is mainly used in the study of oxidative stress-related diseases (such as cardiovascular diseases, neurodegenerative diseases, cancer) and immune regulation mechanisms .
    NADPH
  • HY-13948A
    Angiotensin II human acetate
    Maximum Cited Publications
    222 Publications Verification

    Angiotensin II acetate; Ang II acetate; DRVYIHPF acetate

    		 Angiotensin Receptor Apoptosis Cardiovascular Disease Infection Metabolic Disease Inflammation/Immunology Cancer
    Angiotensin II human (Angiotensin II) acetate is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human acetate plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human acetate stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human acetate induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human acetate also induces apoptosis. Angiotensin II human acetate induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
    Angiotensin II human acetate
  • HY-N0390S1
    L-Glutamine-13C5
    Maximum Cited Publications
    9 Publications Verification

    L-Glutamic acid 5-amide-13C5

    		 Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine- 13C5 is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine-13C5
  • HY-N0390S
    L-Glutamine-15N
    3 Publications Verification

    L-Glutamic acid 5-amide-15N

    		 Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine- 15N is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine-15N
  • HY-N0390S8
    L-Glutamine-15N2
    1 Publications Verification

    L-Glutamic acid 5-amide-15N2

    		 Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine- 15N2 is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine-15N2
  • HY-N0513
    Loganic acid

    		Reactive Oxygen Species (ROS) Phosphatase NF-κB Keap1-Nrf2 Metabolic Disease Inflammation/Immunology
    Loganic acid is an iridoid isolated from cornelian cherry fruits. Loganic acid inhibits NF-κB signaling pathway, activates Nrf2 signaling pathway, exhibits anti-inflammatory activity. Loganic acid can modulate diet-induced atherosclerosis and redox status. Loganic acid has strong free radical scavenging activity and remarkable cyto-protective effect against heavy metal mediated toxicity. Loganic acid is orally active .
    Loganic acid
  • HY-N0390S9
    L-Glutamine-15N-1
    3 Publications Verification

    L-Glutamic acid 5-amide-15N-1

    		 Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine- 15N-1 is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine-15N-1
  • HY-N0390S2
    L-Glutamine-d5
    1 Publications Verification

    L-Glutamic acid 5-amide-d5

    		 Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine-d5 is the deuterium labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine-d5
  • HY-N0390S6
    L-Glutamine-13C5,15N2

    L-Glutamic acid 5-amide-13C5,15N2

    		 Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine- 13C5, 15N2 is the 13C- and 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine-13C5,15N2
  • HY-131898
    PTIO
    1 Publications Verification

    		 NO Synthase Biochemical Assay Reagents Others
    PTIO is a specific scavenger of NO and redox mediator. PTIO reacts with •NO to form the corresponding imino nitroxides and •NO2. PTIO enhances organic contaminants oxidation by permanganate .
    PTIO
  • HY-120475
    PBT434
    2 Publications Verification

    ATH434

    		 α-synuclein Neurological Disease
    PBT434 is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 has the potential for the research of Parkinson’s disease (PD) .
    PBT434
  • HY-W614507
    Dihydronicotinamide riboside

    		NADPH Oxidase Apoptosis Bcl-2 Family Metabolic Disease Cancer
    Dihydronicotinamide riboside is a potent NAD + concentration enhancer. Dihydronicotinamide riboside modulates targets BAX, PUMA, NQO2, and IκB kinase. Dihydronicotinamide riboside mediates apoptosis, induces pro-oxidant activity, mitochondrial dysfunction, metabolic dysregulation, redox modulation, and pro-inflammatory M1 phenotype induction. Dihydronicotinamide riboside increases intracellular and mitochondrial NAD + levels, maintains cell survival against NAD +-depleting genotoxins. Dihydronicotinamide riboside can be used for the research of hepatocellular carcinoma .
    Dihydronicotinamide riboside
  • HY-113410
    3-Methylglutaric acid

    		Na+/K+ ATPase Mitochondrial Metabolism Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease
    3-Methylglutaric acid is a non-selective inhibitor of mitochondrial function and Na +, K +-ATPase, with an inhibition rate of 30% on rat cortical synaptosomal Na +, K +-ATPase. 3-Methylglutaric acid can induce reactive oxygen species (ROS) generation, thereby causing oxidative damage and inhibiting mitochondrial redox potential and ion pump function of cell membranes. 3-Methylglutaric acid can be used to study the neuropathological mechanisms of metabolic diseases and the role of oxidative stress-mediated neuronal damage in neurodegeneration .
    3-Methylglutaric acid
  • HY-13568
    Benoxaprofen

    LRCL 3794

    		 Cytochrome P450 COX Lipoxygenase PGE synthase Inflammation/Immunology
    Benoxaprofen (LRCL 3794) is a nonsteroidal anti-inflammatory agent that blocks the biosynthesis of inflammatory mediators such as leukotrienes and prostaglandins by inhibiting 5-LOX, PGH2 synthase and cytochrome P-450. Benoxaprofen exhibits significant toxicity: it not only alters cellular redox status, uncouples oxidative phosphorylation and disrupts calcium ion homeostasis, but also causes liver injury through the formation of covalent adducts between its active metabolites and hepatic proteins. Benoxaprofen shows strong phototoxicity under ultraviolet irradiation, and induces erythrocyte lysis, mast cell degranulation and histamine release. Benoxaprofen is widely used in studies of urticaria and related phototoxic mechanisms .
    Benoxaprofen
  • HY-114243
    DpC

    		NF-κB JNK Caspase Apoptosis Neurological Disease Cancer
    DpC is a selective, orally active iron chelator with anticancer activity. DpC acts on signaling pathway-related targets such as JNK, NF-κB, and its activity is competitively inhibited by another iron chelator Dp44mT (HY-18973). By chelating intracellular iron and copper ions in tumor cells to form redox-active complexes, DpC induces oxidative stress, activates the JNK, NF-κB pathways and downregulates IκBα, upregulates the expressions of neuroglobin and cytoglobin, activates caspase 3/9 to induce tumor cell apoptosis. It also overcomes P-glycoprotein-mediated multidrug resistance through a lysosome-targeting mechanism, and exhibits broad-spectrum synergistic effects when combined with various chemotherapeutic agents. DpC inhibits tumor metastasis and increases TNF-α levels in the tumor microenvironment to enhance endogenous immune responses. DpC is applicable to the research of various malignancies including neuroblastoma, pancreatic cancer, prostate cancer, lung cancer, and breast cancer .
    DpC
  • HY-12809
    Optovin
    1 Publications Verification

    		 TRP Channel Neurological Disease
    Optovin is a reversible photoactivated TRPA1 ligand that enables light-mediated neuronal excitation. Optovin activates TRPA1 via structure-dependent photochemical reactions with redox-sensitive cysteine residues .
    Optovin
  • HY-131943
    DS44960156

    		Methylenetetrahydrofolate Dehydrogenase (MTHFD) Neurological Disease Cancer
    DS44960156 is a selective MTHFD2 inhibitor with moderate to low blood-brain barrier penetration (IC50=1.6 μM, Ki=1.23 μM). DS44960156 specifically binds to the active site of MTHFD2, disrupts redox homeostasis and blocks serine-mediated one-carbon metabolism, thereby increasing the NAD +/NADH ratio and ROS levels. DS44960156 not only effectively inhibits the proliferation of glioma cells, but also enhances the sensitivity of cells to glutamine starvation-induced death. DS44960156 binds to plasma proteins, shows no mutagenicity, carcinogenicity or acute oral toxicity, and serves as a research agent for glioblastoma multiforme and other cancers .
    DS44960156
  • HY-N0390R
    L-Glutamine (Standard)
    25+ Cited Publications

    L-Glutamic acid 5-amide (Standard)

    		 Reference Standards mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine (Standard) is the analytical standard of L-Glutamine (HY-N0390). This product is intended for research and analytical applications. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine (Standard)
  • HY-13948B
    Angiotensin II human TFA
    Maximum Cited Publications
    222 Publications Verification

    Angiotensin II TFA; Ang II TFA; DRVYIHPF TFA

    		 Angiotensin Receptor Apoptosis Cardiovascular Disease Metabolic Disease Cancer
    Angiotensin II human (Angiotensin II) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human TFA plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human TFA stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human TFA induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human TFA also induces apoptosis. Angiotensin II human TFA induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway .
    Angiotensin II human TFA
  • HY-40145
    1-Boc-3-iodoazetidine

    		Drug Intermediate Others
    1-Boc-3-iodoazetidine acts as a bifunctional additive for lithium-oxygen (Li-O2) batteries and can be used to enhance the performance of Li-O2 batteries. 1-Boc-3-iodoazetidine is applied in the synthesis of C3-functionalized azetidines and C2-functionalized azetidines via a lithium/iodine exchange or β-elimination/lithiation reaction sequence .
    1-Boc-3-iodoazetidine
  • HY-W004570
    5-Nitro-1,10-phenanthroline

    5-NP

    		 Endogenous Metabolite Infection
    5-Nitro-1,10-phenanthroline (5-NP), is a o-Phenanthroline (HY-W004544) derivative, as a mediator of glucose oxidase (GOX) with antituberculous activity. 5-Nitro-1,10-phenanthroline can be applied as redox mediators for oxidases and is suitable for the development of reagent-less biosensors and biofuel cells .
    5-Nitro-1,10-phenanthroline
  • HY-W097009
    Violuric acid

    		Biochemical Assay Reagents Others
    Violuric acid is a redox mediator used in the laccase system. The violuric acid assay is a method to ascertain that the high-redox potential of laccase is not lost during directed evolution .
    Violuric acid
  • HY-120475A
    PBT434 mesylate
    2 Publications Verification

    ATH434 mesylate

    		 α-synuclein Neurological Disease
    PBT434 methanesulfonate is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 methanesulfonate can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 methanesulfonate inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 methanesulfonate prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 methanesulfonate has the potential for the research of Parkinson’s disease (PD) .
    PBT434 mesylate
  • HY-N0390S5
    L-Glutamine-1-13C
    1 Publications Verification

    L-Glutamic acid 5-amide-1-13C

    		 Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine-1- 13C is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine-1-13C
  • HY-N0390S4
    L-Glutamine-5-13C

    L-Glutamic acid 5-amide-5-13C

    		 Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine-5- 13C is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine-5-13C
  • HY-N0390S3
    L-Glutamine-13C5,15N2,d5

    L-Glutamic acid 5-amide-13C5,15N2,d5

    		 Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine- 13C5, 15N2,d5 is the deuterium, 13C-, and 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine-13C5,15N2,d5
  • HY-D0272
    2,3,4-Trihydroxybenzophenone

    		Estrogen Receptor/ERR Metabolic Disease
    2,3,4-Trihydroxybenzophenone is a hydroxylated benzophenone UV filter with estrogenic activity. 2,3,4-Trihydroxybenzophenone is a quorum sensing inhibitor and an EC 1.14.18.1 (tyrosinase) inhibitor. 2,3,4-Trihydroxybenzophenone is also a human urinary metabolite, a rat metabolite and a drug metabolite .
    2,3,4-Trihydroxybenzophenone
  • HY-W287569
    STK683963

    		Atg4 Autophagy Cancer
    STK683963 is a strong activator of cellular ATG4B activity. STK683963 can act as a mediator of redox-regulation of ATG4B in cells. STK683963 can be used for the research of cancer .
    STK683963
  • HY-125953
    Ceramide (Egg)

    Ceramide (Egg, Chicken)

    		 JNK p38 MAPK Phosphatase Akt Survivin CDK mTOR Apoptosis Autophagy Reactive Oxygen Species (ROS) Neurological Disease Cancer
    Ceramide (Egg) (Ceramide (Egg, Chicken)) is a ceramide from chicken. Ceramide (Egg) is a sphingomyelin signaling pathway second messenger. Ceramide (Egg) activates PP2A, JNK, p38 MAPK, CAPK, ceramide-activated protein phosphatase, Vav, PKCζ, and SAPK/JNK cascade. Ceramide (Egg) downregulates or inhibits AKT, survivin, CDK2, mTOR, and FLIP. Ceramide (Egg) mediates apoptosis, autophagy, cell cycle arrest, mitochondrial dysfunction, redox state shifts, and ROS generation. Ceramide (Egg) can be used for the research of cancer and neurological disease .
    Ceramide (Egg)
  • HY-Y0607S1
    4-Nitrobenzoic acid-d2

    		Isotope-Labeled Compounds Drug Intermediate Others
    4-Nitrobenzoic acid-d2 is the deuterium labeled 4-Nitrobenzoic acid (HY-Y0607). 4-Nitrobenzoic acid acts as a redox mediator and electron transfer promoter. 4-Nitrobenzoic acid accepts electrons from reduced glucose oxidase and transfers them to the electrode to facilitate the glucose oxidation reaction, while minimizing the formation of protonated amino groups .
    4-Nitrobenzoic acid-d2
  • HY-120475B
    PBT434 free base

    ATH434 free base

    		 α-synuclein Neurological Disease
    PBT434 (ATH434) free base is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 free base can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 free base inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 free base prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 free base has the potential for the research of Parkinson’s disease (PD) .
    PBT434 free base
  • HY-131898R
    PTIO (Standard)

    		NO Synthase Biochemical Assay Reagents Others
    PTIO (Standard) is the analytical standard of PTIO. This product is intended for research and analytical applications. PTIO is a specific scavenger of NO and redox mediator. PTIO reacts with •NO to form the corresponding imino nitroxides and •NO2. PTIO enhances organic contaminants oxidation by permanganate .
    PTIO (Standard)
  • HY-N0513R
    Loganic acid (Standard)

    		Reference Standards Reactive Oxygen Species (ROS) Phosphatase NF-κB Keap1-Nrf2 Metabolic Disease Inflammation/Immunology
    Loganic acid (Standard) is the analytical standard of Loganic acid. This product is intended for research and analytical applications. Loganic acid is an iridoid isolated from cornelian cherry fruits. Loganic acid inhibits NF-κB signaling pathway, activates Nrf2 signaling pathway, exhibits anti-inflammatory activity. Loganic acid can modulate diet-induced atherosclerosis and redox status. Loganic acid has strong free radical scavenging activity and remarkable cyto-protective effect against heavy metal mediated toxicity. Loganic acid is orally active .
    Loganic acid (Standard)
  • HY-113410S
    3-Methylglutaric acid-d4

    		Isotope-Labeled Compounds Na+/K+ ATPase Mitochondrial Metabolism Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease
    3-Methylglutaric acid-d4 is the deuterium labeled 3-Methylglutaric acid (HY-113410). 3-Methylglutaric acid is a non-selective inhibitor of mitochondrial function and Na +, K +-ATPase, with an inhibition rate of 30% on rat cortical synaptosomal Na +, K +-ATPase. 3-Methylglutaric acid can induce reactive oxygen species (ROS) generation, thereby causing oxidative damage and inhibiting mitochondrial redox potential and ion pump function of cell membranes. 3-Methylglutaric acid can be used to study the neuropathological mechanisms of metabolic diseases and the role of oxidative stress-mediated neuronal damage in neurodegeneration .
    3-Methylglutaric acid-d4
  • HY-113410R
    3-Methylglutaric acid (Standard)

    		Reference Standards Na+/K+ ATPase Mitochondrial Metabolism Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease
    3-Methylglutaric acid (Standard) is the analytical standard of 3-Methylglutaric acid (HY-113410). This product is intended for research and analytical applications. 3-Methylglutaric acid is a non-selective inhibitor of mitochondrial function and Na +, K +-ATPase, with an inhibition rate of 30% on rat cortical synaptosomal Na +, K +-ATPase. 3-Methylglutaric acid can induce reactive oxygen species (ROS) generation, thereby causing oxidative damage and inhibiting mitochondrial redox potential and ion pump function of cell membranes. 3-Methylglutaric acid can be used to study the neuropathological mechanisms of metabolic diseases and the role of oxidative stress-mediated neuronal damage in neurodegeneration .
    3-Methylglutaric acid (Standard)
  • HY-W778179
    Benoxaprofen-13C,d3

    LRCL 3794-13C,d3

    		 Isotope-Labeled Compounds COX Cytochrome P450 Lipoxygenase PGE synthase Inflammation/Immunology
    Benoxaprofen- 13C, d3 is the 13C-labeled Benoxaprofen (HY-13568). Benoxaprofen (LRCL 3794) is a nonsteroidal anti-inflammatory agent that blocks the biosynthesis of inflammatory mediators such as leukotrienes and prostaglandins by inhibiting 5-LOX, PGH2 synthase and cytochrome P-450. Benoxaprofen exhibits significant toxicity: it not only alters cellular redox status, uncouples oxidative phosphorylation and disrupts calcium ion homeostasis, but also causes liver injury through the formation of covalent adducts between its active metabolites and hepatic proteins. Benoxaprofen shows strong phototoxicity under ultraviolet irradiation, and induces erythrocyte lysis, mast cell degranulation and histamine release. Benoxaprofen is widely used in studies of urticaria and related phototoxic mechanisms .
    Benoxaprofen-13C,d3
  • HY-13568R
    Benoxaprofen (Standard)

    LRCL 3794 (Standard)

    		 Reference Standards COX Cytochrome P450 Lipoxygenase PGE synthase Inflammation/Immunology
    Benoxaprofen (Standard) is the analytical standard of Benoxaprofen. This product is intended for research and analytical applications. Benoxaprofen (LRCL 3794) is a nonsteroidal anti-inflammatory agent that blocks the biosynthesis of inflammatory mediators such as leukotrienes and prostaglandins by inhibiting 5-LOX, PGH2 synthase and cytochrome P-450. Benoxaprofen exhibits significant toxicity: it not only alters cellular redox status, uncouples oxidative phosphorylation and disrupts calcium ion homeostasis, but also causes liver injury through the formation of covalent adducts between its active metabolites and hepatic proteins. Benoxaprofen shows strong phototoxicity under ultraviolet irradiation, and induces erythrocyte lysis, mast cell degranulation and histamine release. Benoxaprofen is widely used in studies of urticaria and related phototoxic mechanisms .
    Benoxaprofen (Standard)
  • HY-N0390S7
    L-Glutamine-15N2,d5

    L-Glutamic acid 5-amide-15N2,d5

    		 Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine- 15N2,d5 is the deuterium and 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine-15N2,d5
  • HY-W004570R
    5-Nitro-1,10-phenanthroline (Standard)

    5-NP (Standard)

    		 Endogenous Metabolite Reference Standards Infection
    5-Nitro-1,10-phenanthroline (Standard) (5-NP (Standard)) is the analytical standard of 5-Nitro-1,10-phenanthroline (HY-W004570). This product is intended for research and analytical applications. 5-Nitro-1,10-phenanthroline (5-NP), is a o-Phenanthroline (HY-W004544) derivative, as a mediator of glucose oxidase (GOX) with antituberculous activity. 5-Nitro-1,10-phenanthroline can be applied as redox mediators for oxidases and is suitable for the development of reagent-less biosensors and biofuel cells .
    5-Nitro-1,10-phenanthroline (Standard)
  • HY-120825
    QD 232

    		Apoptosis DNA/RNA Synthesis Reactive Oxygen Species (ROS) Keap1-Nrf2 Cancer
    QD 232 is a quinazolinedione-based ROS inducer and an apoptosis inducer with cytotoxicity and redox regulatory activity. QD 232 promotes ROS accumulation, activates the NRF2-mediated oxidative stress response and unfolded protein response pathways, and upregulates downstream antioxidant and stress response genes. QD 232 inhibits mtDNA transcription driven by HSP2 and LSP promoters, and impairs mitochondrial oxidative phosphorylation function. QD 232 induces apoptosis of pancreatic ductal adenocarcinoma cells and exerts cytotoxicity against gemcitabine (HY-17026)-resistant pancreatic ductal adenocarcinoma cells. QD 232 delays tumor growth in a mouse pancreatic cancer xenograft model .
    QD 232
  • HY-112005G
    DOPE

    Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine

    		 Ferroptosis Glutathione Peroxidase ACSL Family Amino acid Transporter Neurological Disease Inflammation/Immunology
    DOPE GMP is DOPE (HY-112005) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOPE (Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine) is an orally active inhibitor of ferroptosis with anti-inflammatory and intestinal barrier maintenance activities. DOPE regulates the expression of ACSL4, SLC7A11 and GPX4 to restore the redox system balance, thereby reducing the levels of lipid peroxides, iron ions and intestinal inflammatory factors (IL-1β and IL-6). DOPE promotes the migration and proliferation of intestinal epithelial cells and increases the level of tight junction proteins; it also destabilizes endosomal membranes, mediates the conjugation of RVG peptides with mesenchymal stem cell-derived exosomes to enhance brain targeting. DOPE can be applied to research related to neonatal necrotizing enterocolitis and Alzheimer's disease .
    DOPE
  • HY-N0390G
    L-Glutamine

    		mTOR NF-κB STAT HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine GMP is L-Glutamine (HY-N0390) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: